{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:57:22Z","timestamp":1790899042898,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["82170388"],"award-info":[{"award-number":["82170388"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shanghai Technology Research Leader Program","award":["21XD1434700"],"award-info":[{"award-number":["21XD1434700"]}]},{"name":"the Cardiac rehabilitation fund by the International Medical Exchange Foundation","award":["Z-2019-42-1908-3"],"award-info":[{"award-number":["Z-2019-42-1908-3"]}]},{"name":"Grant for the construction of Innovative Flagship Hospital for Integrated Traditional Chinese and Western Medicine","award":["ZY(2021-2023)-0205-05"],"award-info":[{"award-number":["ZY(2021-2023)-0205-05"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"DOI":"10.1186\/s12944-024-02294-8","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T07:02:41Z","timestamp":1727420561000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Estimating the effect of inclisiran on hypercholesterolemia and primary prevention of cardiovascular disease: the NHANES 1999\u20132018 study"],"prefix":"10.1186","volume":"23","author":[{"given":"Haonan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengfeng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"issue":"17","key":"2294_CR1","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1161\/CIRCULATIONAHA.121.057889","volume":"145","author":"RS Vasan","year":"2022","unstructured":"Vasan RS, Enserro DM, Xanthakis V, Beiser AS, Seshadri S. Temporal trends in the remaining lifetime risk of Cardiovascular Disease among Middle-aged adults across 6 decades: the Framingham Study. Circulation. 2022;145(17):1324\u201338.","journal-title":"Circulation"},{"issue":"10053","key":"2294_CR2","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/S0140-6736(16)31460-X","volume":"388","author":"regional Global","year":"2016","unstructured":"Global regional. National disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990\u20132015: a systematic analysis for the global burden of Disease Study 2015. Lancet (London England). 2016;388(10053):1603\u201358.","journal-title":"Lancet (London England)"},{"issue":"10","key":"2294_CR3","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41569-021-00541-4","volume":"18","author":"A Pirillo","year":"2021","unstructured":"Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL. Global epidemiology of dyslipidaemias. Nat Reviews Cardiol. 2021;18(10):689\u2013700.","journal-title":"Nat Reviews Cardiol"},{"issue":"6","key":"2294_CR4","doi-asserted-by":"publisher","first-page":"e001800","DOI":"10.1161\/JAHA.112.001800","volume":"1","author":"PH Jones","year":"2012","unstructured":"Jones PH, Nair R, Thakker KM. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc. 2012;1(6):e001800.","journal-title":"J Am Heart Assoc"},{"issue":"18","key":"2294_CR5","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/jama.2022.5218","volume":"327","author":"L R\u00e4ber","year":"2022","unstructured":"R\u00e4ber L, Ueki Y, Otsuka T, et al. Effect of Alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with Acute myocardial infarction: the PACMAN-AMI Randomized Clinical Trial. JAMA. 2022;327(18):1771\u201381.","journal-title":"JAMA"},{"issue":"1","key":"2294_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609243","volume":"376","author":"K Fitzgerald","year":"2017","unstructured":"Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376(1):41\u201351.","journal-title":"N Engl J Med"},{"issue":"5","key":"2294_CR7","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1210\/clinem\/dgab876","volume":"107","author":"CA Aguilar-Salinas","year":"2022","unstructured":"Aguilar-Salinas CA, G\u00f3mez-D\u00edaz RA, Corral P. New therapies for primary hyperlipidemia. J Clin Endocrinol Metab. 2022;107(5):1216\u201324.","journal-title":"J Clin Endocrinol Metab"},{"key":"2294_CR8","doi-asserted-by":"crossref","unstructured":"Al Shaer D, Al Musaimi O, Albericio F, de la Torre BG. 2021 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals (Basel, Switzerland). 2022;15(2).","DOI":"10.3390\/ph15020222"},{"key":"2294_CR9","unstructured":"US FDA approves expanded indication for Novartis Leqvio\u00ae. (inclisiran). https:\/\/www.novartis.com\/us-en\/news\/media-releases\/us-fda-approves-expanded-indication-novartis-leqvio-inclisiran-include-treatment-adults-high-ldl-c-and-who-are-increased-risk-heart-disease. Accessed 6 Sep 2024."},{"issue":"15","key":"2294_CR10","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"KK Ray","year":"2017","unstructured":"Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at High Cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430\u201340.","journal-title":"N Engl J Med"},{"issue":"2","key":"2294_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","volume":"11","author":"KK Ray","year":"2023","unstructured":"Ray KK, Troquay RPT, Visseren FLJ, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023;11(2):109\u201319.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"16","key":"2294_CR12","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520\u201330.","journal-title":"N Engl J Med"},{"issue":"16","key":"2294_CR13","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of Inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u201319.","journal-title":"N Engl J Med"},{"issue":"48","key":"2294_CR14","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1093\/eurheartj\/ehac615","volume":"43","author":"KK Ray","year":"2022","unstructured":"Ray KK, Kallend D, Leiter LA, et al. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 2022;43(48):5047\u201357.","journal-title":"Eur Heart J"},{"issue":"24","key":"2294_CR15","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/j.jacc.2023.10.007","volume":"82","author":"RS Wright","year":"2023","unstructured":"Wright RS, Koenig W, Landmesser U, et al. Safety and Tolerability of Inclisiran for treatment of Hypercholesterolemia in 7 clinical trials. J Am Coll Cardiol. 2023;82(24):2251\u201361.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2294_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/eurheartj\/ehac594","volume":"44","author":"KK Ray","year":"2023","unstructured":"Ray KK, Raal FJ, Kallend DG, et al. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2023;44(2):129\u201338.","journal-title":"Eur Heart J"},{"key":"2294_CR17","doi-asserted-by":"publisher","first-page":"112227","DOI":"10.1016\/j.biopha.2021.112227","volume":"143","author":"P Scicchitano","year":"2021","unstructured":"Scicchitano P, Milo M, Mallamaci R, et al. Inclisiran in lipid management: a literature overview and future perspectives. Biomed Pharmacother. 2021;143:112227.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"2294_CR18","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2217\/fca-2018-0067","volume":"14","author":"RM Stoekenbroek","year":"2018","unstructured":"Stoekenbroek RM, Kallend D, Wijngaard PL, Kastelein JJ. Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program. Future Cardiol. 2018;14(6):433\u201342.","journal-title":"Future Cardiol"},{"key":"2294_CR19","unstructured":"Heeringa S, West BT, Berglund PA. Applied survey data analysis. Second edition. ed. Boca Raton, FL: CRC Press, Taylor & Francis Group; 2017."},{"key":"2294_CR20","doi-asserted-by":"crossref","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082\u2013e1143.","DOI":"10.1161\/CIR.0000000000000698"},{"issue":"1","key":"2294_CR21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. EUR HEART J. 2020;41(1):111\u201388.","journal-title":"EUR HEART J"},{"issue":"6","key":"2294_CR22","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","volume":"117","author":"RB D\u2019Agostino","year":"2008","unstructured":"D\u2019Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743\u201353.","journal-title":"Circulation"},{"issue":"10","key":"2294_CR23","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jacc.2018.06.046","volume":"72","author":"BA Ference","year":"2018","unstructured":"Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of lipids on Cardiovascular Health: JACC Health Promotion Series. J Am Coll Cardiol. 2018;72(10):1141\u201356.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"2294_CR24","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1001\/jamacardio.2021.3508","volume":"6","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Pletcher MJ, Vittinghoff E, et al. Association between Cumulative Low-Density Lipoprotein Cholesterol Exposure during Young Adulthood and Middle Age and Risk of Cardiovascular events. JAMA Cardiol. 2021;6(12):1406\u201313.","journal-title":"JAMA Cardiol"},{"issue":"8","key":"2294_CR25","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1001\/jama.2022.13493","volume":"328","author":"J Jin","year":"2022","unstructured":"Jin J. Statins for the Prevention of Cardiovascular Disease. JAMA. 2022;328(8):786.","journal-title":"JAMA"},{"issue":"8","key":"2294_CR26","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","volume":"24","author":"G Dubuc","year":"2004","unstructured":"Dubuc G, Chamberland A, Wassef H, et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vascular Biology. 2004;24(8):1454\u20139.","journal-title":"Arterioscler Thromb Vascular Biology"},{"issue":"47","key":"2294_CR27","doi-asserted-by":"publisher","first-page":"48865","DOI":"10.1074\/jbc.M409699200","volume":"279","author":"S Benjannet","year":"2004","unstructured":"Benjannet S, Rhainds D, Essalmani R, et al. NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem. 2004;279(47):48865\u201375.","journal-title":"J Biol Chem"},{"issue":"18","key":"2294_CR28","doi-asserted-by":"publisher","first-page":"7100","DOI":"10.1073\/pnas.0402133101","volume":"101","author":"KN Maxwell","year":"2004","unstructured":"Maxwell KN, Breslow JL. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci USA. 2004;101(18):7100\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2294_CR29","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1073\/pnas.0409736102","volume":"102","author":"KN Maxwell","year":"2005","unstructured":"Maxwell KN, Fisher EA, Breslow JL. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci USA. 2005;102(6):2069\u201374.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"48","key":"2294_CR30","doi-asserted-by":"publisher","first-page":"50630","DOI":"10.1074\/jbc.M410077200","volume":"279","author":"SW Park","year":"2004","unstructured":"Park SW, Moon YA, Horton JD. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin\/kexin type 9a in mouse liver. J Biol Chem. 2004;279(48):50630\u20138.","journal-title":"J Biol Chem"},{"issue":"15","key":"2294_CR31","doi-asserted-by":"publisher","first-page":"5374","DOI":"10.1073\/pnas.0501652102","volume":"102","author":"S Rashid","year":"2005","unstructured":"Rashid S, Curtis DE, Garuti R, et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci USA. 2005;102(15):5374\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"2294_CR32","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264\u201372.","journal-title":"N Engl J Med"},{"issue":"18","key":"2294_CR33","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical outcomes in patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"22","key":"2294_CR34","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"issue":"2","key":"2294_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/11535240-000000000-00000","volume":"10","author":"D Vulic","year":"2010","unstructured":"Vulic D, Lee BT, Dede J, Lopez VA, Wong ND. Extent of control of cardiovascular risk factors and adherence to recommended therapies in US multiethnic adults with coronary heart disease: from a 2005\u20132006 national survey. Am J Cardiovasc Drugs. 2010;10(2):109\u201314.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"9","key":"2294_CR36","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.jval.2023.05.002","volume":"26","author":"DA Ostwald","year":"2023","unstructured":"Ostwald DA, Schmitt M, Peristeris P, Gerritzen T, Durand A. The societal impact of Inclisiran in England: evidence from a Population Health Approach. Value Health. 2023;26(9):1353\u201362.","journal-title":"Value Health"},{"issue":"9","key":"2294_CR37","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s40273-020-00948-w","volume":"38","author":"N Kam","year":"2020","unstructured":"Kam N, Perera K, Zomer E, Liew D, Ademi Z. Inclisiran as Adjunct lipid-lowering therapy for patients with Cardiovascular Disease: a cost-effectiveness analysis. PharmacoEconomics. 2020;38(9):1007\u201320.","journal-title":"PharmacoEconomics"},{"key":"2294_CR38","doi-asserted-by":"publisher","first-page":"n1537","DOI":"10.1136\/bmj.n1537","volume":"374","author":"T Cai","year":"2021","unstructured":"Cai T, Abel L, Langford O, et al. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. BMJ. 2021;374:n1537.","journal-title":"BMJ"},{"key":"2294_CR39","doi-asserted-by":"crossref","unstructured":"Kanchi R, Perlman SE, Chernov C, in Cardiovascular Disease Risk Factors among New York City Adults. Gender and Race Disparities : New York City Health and Nutrition Examination Survey (NYC HANES) 2013\u20132014. Journal of urban health-bulletin of the New York Academy of Medicine. 2018;95(6):801\u2013812.","DOI":"10.1007\/s11524-018-0287-x"},{"issue":"25","key":"2294_CR40","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1093\/eurheartj\/ehy217","volume":"39","author":"MJ Budoff","year":"2018","unstructured":"Budoff MJ, Young R, Burke G, et al. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA). Eur Heart J. 2018;39(25):2401\u20138.","journal-title":"Eur Heart J"},{"issue":"2","key":"2294_CR41","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jacc.2022.04.047","volume":"80","author":"Y Gao","year":"2022","unstructured":"Gao Y, Isakadze N, Duffy E, et al. Secular trends in Risk profiles among adults with Cardiovascular Disease in the United States. J Am Coll Cardiol. 2022;80(2):126\u201337.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"2294_CR42","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/oxfordjournals.aje.a009387","volume":"147","author":"MM Bergmann","year":"1998","unstructured":"Bergmann MM, Byers T, Freedman DS, Mokdad A. Validity of self-reported diagnoses leading to hospitalization: a comparison of self-reports with hospital records in a prospective study of American adults. Am J Epidemiol. 1998;147(10):969\u201377.","journal-title":"Am J Epidemiol"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-024-02294-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-024-02294-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-024-02294-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T07:16:53Z","timestamp":1727421413000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-024-02294-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2294"],"URL":"https:\/\/doi.org\/10.1186\/s12944-024-02294-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4727339\/v1","asserted-by":"object"}]},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"12 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study utilized de-identified publicly available data and does not qualify for institutional review board review. The National Health and Nutrition Examination Survey obtains consent to participate from all subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. No individual data or images are used in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"313"}}